Professor Iain McNeish

Affiliate (School of Cancer Sciences)

RI Cancer Sciences, Beatson Institute, Garscube Estate, Switchback Road, G61 1BD

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1996

Number of items: 91.

2024

Dareng, E. O. et al. (2024) Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. American Journal of Human Genetics, 111(6), pp. 1061-1083. (doi: 10.1016/j.ajhg.2024.04.011) (PMID:38723632)

Ramachandran, D. et al. (2024) Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease. npj Genomic Medicine, 9(1), 19. (doi: 10.1038/s41525-024-00395-y) (PMID:38443389) (PMCID:PMC10915171)

2023

Nikolatou, K. et al. (2023) PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO Journal, 42, e1139. (doi: 10.15252/embj.2023113987) (PMID:37577760) (PMCID:PMC10505920)

Smith, P. et al. (2023) The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nature Communications, 14(1), 4387. (doi: 10.1038/s41467-023-39867-7) (PMID:37474499) (PMCID:PMC10359414)

Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)

2022

Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

2021

Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)

Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Hinsley, Samantha ORCID: https://orcid.org/0000-0001-6903-4688, Mcneish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586, Roxburgh, Patricia ORCID: https://orcid.org/0000-0001-9869-591X and Glasspool, Rosalind (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

Macintyre, G. et al. (2021) FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. JCO Clinical Cancer Informatics, 5, pp. 176-186. (doi: 10.1200/cci.20.00075) (PMID:33570999)

2020

Talhouk, A. et al. (2020) Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research, 26(20), (doi: 10.1158/1078-0432.CCR-20-0103) (PMID:32554541) (PMCID:PMC7572656)

Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

Blagih, J. et al. (2020) Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Reports, 30(2), 481-496.e6. (doi: 10.1016/j.celrep.2019.12.028) (PMID:31940491) (PMCID:31940491)

2018

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

McGivern, Niamh, El-Helali, Aya, Mullan, Paul, Mcneish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586, Paul Harkin, D, Kennedy, Richard D. and McCabe, Nuala (2018) Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 9(4), pp. 4722-4736. (doi: 10.18632/oncotarget.23524) (PMID:29435137) (PMCID:PMC5797008)

Sierra Gonzalez, P. et al. (2018) Mannose impairs tumour growth and enhances chemotherapy. Nature, 563, pp. 719-723. (doi: 10.1038/s41586-018-0729-3) (PMID:30464341)

2017

Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi: 10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Oza, A. M. et al. (2017) Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 147(2), pp. 267-275. (doi: 10.1016/j.ygyno.2017.08.022) (PMID:28882436)

Coleman, R. L. et al. (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10106), pp. 1949-1961. (doi: 10.1016/S0140-6736(17)32440-6) (PMID:28916367) (PMCID:PMC5901715)

De Munck, Jolien, Binks, Alex, Mcneish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586 and Aerts, Joeri L. (2017) Oncolytic virus-induced cell death and immunity: a match made in heaven? Journal of Leukocyte Biology, 102(3), pp. 631-643. (doi: 10.1189/jlb.5RU0117-040R) (PMID:28720686)

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discovery, 7(9), pp. 984-998. (doi: 10.1158/2159-8290.CD-17-0419) (PMID:28588062) (PMCID:PMC5612362)

Babic, A. et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 28(5), pp. 459-468. (doi: 10.1007/s10552-016-0841-3) (PMID:28050675) (PMCID:PMC5593071)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi: 10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi: 10.1158/1055-9965.EPI-16-0631) (PMID:27677730) (PMCID:PMC5500198)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

Swisher, E. M. et al. (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, 18(1), pp. 75-87. (doi: 10.1016/S1470-2045(16)30559-9) (PMID:27908594)

Weigert, M. et al. (2017) RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 8, 3206. (doi: 10.1038/s41419-017-0110-8) (PMID:29238045) (PMCID:PMC5870599)

2016

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi: 10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Walton, J. et al. (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research, 76(20), pp. 6118-6129. (doi: 10.1158/0008-5472.CAN-16-1272) (PMID:27530326) (PMCID:PMC5802386)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi: 10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Kar, S. P. et al. (2016) Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discovery, 6(9), pp. 1052-1067. (doi: 10.1158/2159-8290.CD-15-1227) (PMID:27432226) (PMCID:PMC5010513)

McNeish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586 (2016) Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype? Annals of Oncology, 27(8), pp. 1366-1368. (doi: 10.1093/annonc/mdw254) (PMID:27358384)

Böhm, S. et al. (2016) Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research, 22(12), pp. 3025-3036. (doi: 10.1158/1078-0432.ccr-15-2657) (PMID:27306793)

Singh, Naveena, Gilks, C. Blake, Hirschowitz, Lynn, Kehoe, Sean, McNeish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586, Miller, Dianne, Naik, Raj, Wilkinson, Nafisa and McCluggage, W. Glenn (2016) Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecologic Oncology, 141(2), pp. 195-198. (doi: 10.1016/j.ygyno.2015.10.022) (PMID:26827965)

Piskorz, A.M. et al. (2016) Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. Annals of Oncology, 27(3), pp. 532-539. (doi: 10.1093/annonc/mdv613) (PMID:26681675) (PMCID:PMC4769995)

Clarke, C. J. et al. (2016) The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology, 26(6), pp. 755-765. (doi: 10.1016/j.cub.2016.01.045) (PMID:26948875) (PMCID:PMC4819511)

Meeks, H. D. et al. (2016) BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. Journal of the National Cancer Institute, 108(2), djv315. (doi: 10.1093/jnci/djv315) (PMID:26586665) (PMCID:PMC4907358)

Tookman, Laura A., Browne, Ashley K., Connell, Claire M., Bridge, Gemma, Ingemarsdotter, Carin K., Dowson, Suzanne, Shibata, Atsushi, Lockley, Michelle, Martin, Sancha and Mcneish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586 (2016) RAD51 and BRCA2 enhance oncolytic adenovirus Type 5 activity in ovarian cancer. Molecular Cancer Research, 14(1), pp. 44-55. (doi: 10.1158/1541-7786.mcr-15-0188-t) (PMID:26452665)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Crosbie, E.J., Edmondson, R.J., Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 and Sasieni, P. (2015) Are rigid management protocols stifling innovation in cancer treatment? BJOG: An International Journal of Obstetrics and Gynaecology, 122(11), pp. 1432-1434. (doi: 10.1111/1471-0528.13449) (PMID:26032865)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Browne, A., Tookman, L.A., Ingemarsdotter, C.K., Bouwman, R.D., Pirlo, K., Wang, Y., Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 and Lockley, M. (2015) Pharmacological inhibition of 3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Research, 75(14), pp. 2811-2821. (doi: 10.1158/0008-5472.can-14-3761) (PMID:25977332)

Ingemarsdotter, C. K. et al. (2015) Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 9(4), pp. 791-805. (doi: 10.1016/j.molonc.2014.12.007) (PMID:25560085)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi: 10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi: 10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi: 10.1038/ng.3185)

2014

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi: 10.1097/IGC.0000000000000289)

Rockall, A. G. et al. (2014) Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Clinical Cancer Research, 20(10), pp. 2751-2760. (doi: 10.1158/1078-0432.CCR-13-2634)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

McNeish, I.A. et al. (2014) A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology, 25(10), pp. 1988-1995. (doi: 10.1093/annonc/mdu363)

2013

Glasspool, R.M. and McNeish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2013) Clear cell carcinoma of ovary and uterus. Current Oncology Reports, 15(6), pp. 566-572. (doi: 10.1007/s11912-013-0346-0)

Leinster, A. et al. (2013) Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB Journal, 27(10), pp. 4244-4253. (doi: 10.1096/fj.13-230441)

Hall, M., Gourley, C., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. and Kaye, S. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 108(2), pp. 250-258. (doi: 10.1038/bjc.2012.541)

Whilding, L., Archibald, K., Kulbe, H., Balkwill, F., Oberg, D. and Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586 (2013) Vaccinia virus induces programmed necrosis in ovarian cancer cells. Molecular Therapy, 21(11), pp. 2074-2086. (doi: 10.1038/mt.2013.195)

2012

Archibald, K.M. et al. (2012) Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 31(48), pp. 4987-4995. (doi: 10.1038/onc.2011.653)

Young, A.-M. et al. (2012) Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Molecular Therapy, 20(9), pp. 1676-1688. (doi: 10.1038/mt.2012.116)

Leinster, D.A. et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Journal of Pathology, 227(2), pp. 136-145. (doi: 10.1002/path.4002)

Saha, A. et al. (2012) Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. International Journal of Gynecological Cancer, 22(4), pp. 566-72. (doi: 10.1097/IGC.0b013e318247727f)

Emeagi, P.U. et al. (2012) Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Research, 72(6), pp. 1342-1352. (doi: 10.1158/0008-5472.CAN-11-2400)

Coley, H.M., Hatzimichael, E., Blagden, S., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Thompson, A., Crook, T. and Syed, N. (2012) Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget, 3(1), pp. 78-83.

Stone, R.L. et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 366(7), pp. 610-618. (doi: 10.1056/NEJMoa1110352)

2011

Ateh, D.D. et al. (2011) The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 32(33), pp. 8538-8547. (doi: 10.1016/j.biomaterials.2011.07.060)

Ledermann, J.A. et al. (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology, 29(28), pp. 3798-804. (doi: 10.1200/JCO.2010.33.5208)

Vaughan, S. et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 11(10), pp. 719-725. (doi: 10.1038/nrc3144)

Coward, J. et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), pp. 6083-6096. (doi: 10.1158/1078-0432.CCR-11-0945)

Syed, N. et al. (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Research, 71(9), pp. 3317-3327. (doi: 10.1158/0008-5472.CAN-10-2048)

Ledermann, J.A. et al. (2011) Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer, 21(4), pp. 763-70. (doi: 10.1097/IGC.0b013e31821b2669)

Connell, C.M., Shibata, A., Tookman, L.A., Archibald, K.M., Flak, M.B., Pirlo, K.J., Lockley, M., Wheatley, S.P. and McNeish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2011) Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. Journal of Clinical Investigation, 121(4), pp. 1283-1297. (doi: 10.1172/JCI43976)

Salako, M.A., Kulbe, H., Ingemarsdotter, C.K., Pirlo, K.J., Williams, S.L., Lockley, M., Balkwill, F.R. and McNeish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2011) Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Molecular Therapy, 19(3), pp. 490-499. (doi: 10.1038/mt.2010.247)

2010

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi: 10.1111/IGC.0b013e3181ee1c01)

Harrington, K.J. et al. (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clinical Cancer Research, 16(15), pp. 4005-4015. (doi: 10.1158/1078-0432.CCR-10-0196)

Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, K.J., Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 and Vassaux, G. (2010) Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 37(7), pp. 1377-1385. (doi: 10.1007/s00259-009-1379-3)

Delage, B., Fennell, D.A., Nicholson, L., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Lemoine, N.R., Crook, T. and Szlosarek, P.W. (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. International Journal of Cancer, 126(12), pp. 2762-72. (doi: 10.1002/ijc.25202)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C. ORCID: https://orcid.org/0000-0002-3711-6547, Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586, Nicklin, S. ORCID: https://orcid.org/0000-0002-9691-6210 and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi: 10.3390/v2102290) (PMID:21994621) (PMCID:PMC3185574)

Elmetwali, T., Searle, P.F., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Young, L.S. and Palmer, D.H. (2010) CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 9(52), (doi: 10.1186/1476-4598-9-52)

Flak, M.B., Connell, C.M., Chelala, C., Archibald, K., Salako, M.A., Pirlo, K.J., Lockley, M., Wheatley, S.P., Balkwill, F.R. and Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2010) p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Molecular Cancer, 9(175), (doi: 10.1186/1476-4598-9-175)

Ingemarsdotter, C.K., Baird, S.K., Connell, C.M., Öberg, D., Halldén, G. and McNeish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 29(45), pp. 6051-6063. (doi: 10.1038/onc.2010.335)

2009

Warwick, J., Vardaki, E., Fattizzi, N., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Jeyarajah, A., Oram, D., Hassan, L., Covens, A., Duffy, S. and Reynolds, K. (2009) Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG: An International Journal of Obstetrics and Gynaecology, 116(9), pp. 1225-1241. (doi: 10.1111/j.1471-0528.2009.02213.x)

Coughlan, L., Vallath, S., Saha, A., Flak, M., Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586, Vassaux, G., Marshall, J.F., Hart, I.R. and Thomas, G.J. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Journal of Virology, 83(13), pp. 6416-28. (doi: 10.1128/JVI.00445-09)

Young, A.M. and Mcneish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 5(3), pp. 339-357. (doi: 10.2217/fon.09.11)

2008

Hagemann, T., Lawrence, T., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C. and Balkwill, F.R. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), pp. 1261-1268. (doi: 10.1084/jem.20080108)

Pomel, C., Barton, D.P.J., Mcneish, I. ORCID: https://orcid.org/0000-0002-9387-7586 and Shepherd, J. (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology, 115(7), pp. 808-810. (doi: 10.1111/j.1471-0528.2008.01692.x)

Connell, C.M., Wheatley, S.P. and McNeish, I.A. ORCID: https://orcid.org/0000-0002-9387-7586 (2008) Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Research, 68(19), pp. 7923-7931. (doi: 10.1158/0008-5472.CAN-08-0817)

1996

Muir, K.W. ORCID: https://orcid.org/0000-0001-9535-022X, McNeish, I. ORCID: https://orcid.org/0000-0002-9387-7586, Grosset, D.G. ORCID: https://orcid.org/0000-0002-2757-8203 and Metcalfe, M. (1996) Visualization of cardiac emboli from mitral valve papillary fibroelastoma. Stroke, 27(6), pp. 1133-1134. (PMID:8650729)

This list was generated on Mon Jun 16 04:34:53 2025 BST.

Jump to: Articles

Number of items: 91.

Articles

Sierra Gonzalez, P. et al. (2018) Mannose impairs tumour growth and enhances chemotherapy. Nature, 563, pp. 719-723. (doi: 10.1038/s41586-018-0729-3) (PMID:30464341)

Weigert, M. et al. (2017) RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 8, 3206. (doi: 10.1038/s41419-017-0110-8) (PMID:29238045) (PMCID:PMC5870599)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi: 10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi: 10.1038/ng.3185)

Leinster, D.A. et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Journal of Pathology, 227(2), pp. 136-145. (doi: 10.1002/path.4002)

Emeagi, P.U. et al. (2012) Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Research, 72(6), pp. 1342-1352. (doi: 10.1158/0008-5472.CAN-11-2400)

Stone, R.L. et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 366(7), pp. 610-618. (doi: 10.1056/NEJMoa1110352)

Vaughan, S. et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 11(10), pp. 719-725. (doi: 10.1038/nrc3144)

Coward, J. et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), pp. 6083-6096. (doi: 10.1158/1078-0432.CCR-11-0945)

This list was generated on Mon Jun 16 04:34:53 2025 BST.

We use cookies

Necessary cookies

Analytics cookies

Clarity

Professor Iain McNeish

Publications

2024

2023

2022

2021

2020

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

1996

Articles